ArticleNPJ breast cancer2022
Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer.
Abstract read
In one paragraph
Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Tumor-Infiltrating Lymphocytes as a Predictor of Adjuvant Avelumab Efficacy in Patients with High-risk Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Artificial intelligence-based tumour infiltrating lymphocyte quantification in patients with triple-negative breast cancer: an independent validation study.The Lancet. Oncology · 2026Article
- Prognostic Value of Morphological Characteristics and Immune Microenvironment in High-Grade Serous Cancer (HGSC).Cancers · 2026Article
- AI-assisted image analysis of tumor-infiltrating lymphocytes as a prognostic marker in chemotherapy-naïve luminal breast cancer.NPJ breast cancer · 2026Article
- Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.Nature communications · 2026Observational
- Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.Cancers · 2026Review
- RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer.NPJ breast cancer · 2026Article
- Case Report: Pathologic complete response in triple negative breast cancer treated with anthracycline free regimen.Frontiers in oncology · 2026Article
- Immune system, inflammatory response, and regulated cell death in breast cancer research (Review).Oncology reports · 2026Review
- Advances and challenges in biomarker guided management of triple-negative breast cancer in the era of neoadjuvant chemo-immunotherapy.Frontiers in oncology · 2026Review
- Review
- DNA methylation biomarkers for the diagnosis and treatment management of breast cancer: where are we now?Epigenomics · 2025Review
- Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade.Cell reports. Medicine · 2025Article
- Prognostic and predictive capacity of tumor infiltrating lymphocytes in the MA.20 regional node radiotherapy trial.NPJ breast cancer · 2025Article
- Global Transcriptional Complexity of Estrogen Receptor-Low Positive Breast Cancers in the Prospective Swedish Population-Based SCAN-B Cohort.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- PML localization in tumor associated macrophages as a prognostic marker in triple negative breast cancer.Scientific reports · 2025Article
- High tumor expression of CTLA4 identifies lymph node-negative basal-like breast cancer patients with excellent prognosis.Communications medicine · 2025Article
- Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies.Cancers · 2025Review
- High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration.Breast cancer research and treatment · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Sherene LoiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia. sherene.loi@petermac.org.ORCID http://orcid.org/0000-0001-6137-9171
Roberto SalgadoPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-1110-3801
Sylvia AdamsNew York University Langone Health, Perlmutter Cancer Center, New York, NY, USA.
Giancarlo PruneriFondazione Istituto di Ricovero e Cura a Carattere Scientifico-Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy.
Prudence A FrancisPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.ORCID http://orcid.org/0000-0002-7207-9286
Magali Lacroix-TrikiGustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0002-6641-8536
Heikki JoensuuHelsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0003-0281-2507
Maria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy.
Sunil BadveIndiana University, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0001-8861-9980
Sandra DemariaWeill-Cornell Medicine, New York, NY, USA.ORCID http://orcid.org/0000-0003-4426-0499
Robert GrayDana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-5724-4917
Elisabetta MunzoneDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, Italy.ORCID http://orcid.org/0000-0003-3371-3878
Damien DrubayService de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.
Jerome LemonnierR&D UNICANCER, Paris, France.
Christos SotiriouInstitut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.ORCID http://orcid.org/0000-0002-5745-9977
Pirkko Liisa Kellokumpu-LehtinenFaculty of Medicine and Health Technology Tampere University and Tampere University Hospital Tamper, Tamper, Finland.ORCID http://orcid.org/0000-0002-5557-0911
Andrea VingianiFondazione Istituto di Ricovero e Cura a Carattere Scientifico-Isituto Nazionale dei Tumori, Universita degli Studi di Milano, Milan, Italy.
Kathryn GrayFrontier Science & Technology Research Foundation, Boston, MA, USA.
Fabrice AndréGustave Roussy, Université Paris-Saclay, Villejuif, France.ORCID http://orcid.org/0000-0001-5795-8357
Carsten DenkertInstitut für Pathologie, Universitätsklinikum Marburg, Philipps-Universität Marburg, Marburg, Germany.ORCID http://orcid.org/0000-0002-2249-0982
Martine PiccartInstitut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium.
Elvire RoblinService de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.
Stefan MichielsService de Biostatistique et d'Epidémiologie, Gustave Roussy, Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif, France.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of integrating biomarkers into the TNM staging has been emphasized in the 8
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.